M&A Deal Summary

Takeda Acquires LigoCyte Pharmaceuticals

On October 4, 2012, Takeda acquired life science company LigoCyte Pharmaceuticals from Eight Roads for 60M USD

Acquisition Highlights
  • This is Takeda’s 6th transaction in the Life Science sector.
  • This is Takeda’s 8th largest (disclosed) transaction.
  • This is Takeda’s 4th transaction in the United States.
  • This is Takeda’s 1st transaction in Montana.

M&A Deal Summary

Date 2012-10-04
Target LigoCyte Pharmaceuticals
Sector Life Science
Buyer(s) Takeda
Sellers(s) Eight Roads
Deal Type Add-on Acquisition
Deal Value 60M USD
Advisor(s) Sagent Advisors LLC (Financial)
Cooley (Legal)

Target

LigoCyte Pharmaceuticals

Bozeman, Montana, United States
LigoCyte Pharmaceuticals is a privately-held biopharmaceutical company specializing in innovative vaccine products. Its lead product, a vaccine to prevent norovirus gastroenteritis, is in phase I/II of clinical development. LigoCyte Pharmaceuticals was founded in 1998 and is based in Bozeman, Montana.

Search 201,839 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda

Tokyo, Japan

Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.


DEAL STATS #
Overall 6 of 18
Sector (Life Science) 6 of 17
Type (Add-on Acquisition) 6 of 15
State (Montana) 1 of 1
Country (United States) 4 of 12
Year (2012) 1 of 2
Size (of disclosed) 8 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-12-21 Intellikine

La Jolla, California, United States

Intellikine, Inc. is a private company focused on the development of innovative, small molecule drugs targeting the PI3K/mTOR pathway for the treatment of cancer and other serious diseases.

Buy $190M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-11-06 Envoy Therapeutics

Jupiter, Florida, United States

Envoy Therapeutics, Inc. is a privately-held drug discovery company focused on finding new drugs with superior efficacy and fewer side effects than existing treatments.

Buy $140M

Seller(S) 1

SELLER
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.


DEAL STATS #
Overall 10 of 99
Sector (Life Science) 7 of 49
Type (Add-on Acquisition) 6 of 45
State (Montana) 1 of 1
Country (United States) 5 of 60
Year (2012) 2 of 3
Size (of disclosed) 18 of 19
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-10-04 Aclaris

Wayne, Pennsylvania, United States

Aclaris is a clinical stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris was founded in 2012 and is based in Wayne, Pennsylvania.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-10-22 NextWave Pharmaceuticals

Cupertino, California, United States

NextWave Pharmaceuticals is a specialty pharmaceutical company developing extended release OTC and prescription products for children and adults. NextWave Pharmaceuticals was founded in 2005 and is based in Cupertino, California.

Sell $700M